ProSolus, Inc. delivers sophisticated transdermal solutions customized to meet your needs and exceed your expectations. We formulate, develop, and manufacture high-barrier-to-entry transdermal drug delivery products in our state-of-the-art laboratories and manufacturing facility. Our patches are designed with the patient in mind.
What We Do
How We Do It
Our research and development team works collaboratively with our suppliers to create polymers and design combinations of excipients that improve the absorption of medications through the skin without having to resort to exotic permeation enhancers. Focused on what lies ahead, our team continues to explore methods to optimize transdermal drug delivery.
ProSolus is an experienced partner with unrivaled transdermal prowess. Our experts are committed to delivering a customized experience every step of the way concept through completion. Whether you need formulation, development, and/or manufacturing support, we’ll provide sophisticated solutions tailored to your needs.
About ProSolus, Inc.
ProSolus, Inc. is a wholly owned subsidiary of Canoa, Inc. We are focused on formulating and developing high-barrier-to-entry Transdermal Drug Delivery systems (TDDs) for ANDA, NDA, and 505(b)(2) applications.
Our state-of-the art pharma facility in Miami, Florida is managed by a seasoned leadership team with more than 65 years of experience. With the newly completed manufacturing wing and 50 million+ transdermal patch capacity, ProSolus effectively and efficiently delivers results from the conceptual formulation stage, through the clinical stage, to the coating stage completing the cycle and preparing the product for packaging.